CVS Health Corp vs Prospect Capital Corporation — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.49B), while Prospect Capital Corporation trades at $1.83 (market cap $984.89M). The key difference: CVS Health Corp is far larger — about 114.2× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (22.76%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Prospect Capital Corporation for 78 Days on average.
| CVS | PSEC | |
|---|---|---|
Market Cap | $112.49B | $984.89M |
Volume | 8,467,392 | 10,087,405 |
Sector | Health | Financials |
52-Week High | $110.60 | $3.05 |
52-Week Low | $70.08 | $1.82 |
Typical Hold Time | 83 Days | 78 Days |
Enterprise Value | $174.83B | $2.74B |
Dividend Yield | 3.02% | 22.76% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
PSEC trades at $1.82, down 0.55% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company has beaten EPS estimates for the last three quarters, though revenue and net income were negative in 2025. Recent news highlights dividend declarations and management commentary on market opportunities, but financial performance shows volatility with a sharp revenue decline in 2025.
The outlook is mixed; a low P/B ratio of 0.34 suggests potential undervaluation, but negative cash flow and inconsistent profitability pose risks. Analyst sentiment is cautious with a majority Hold rating. Key opportunities include dividend yield and earnings beats, while risks involve financial instability and bearish technical trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →